Phase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson's Disease
Phase of Trial: Phase I/II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs CDNF (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Herantis Pharma
- 13 Mar 2018 Last checked against European Clinical Trials Database record.
- 02 Mar 2018 According to the Herantis Pharma media release, recruitment in this study is expected to be completed in 2018.
- 12 Oct 2017 New trial record